Risk of serious bloodstream infections is low in pediatric hematopoietic stem cell transplant (HSCT) recipients with fevers due to antithymocyte globulins and alemtuzumab
Crossref DOI link: https://doi.org/10.1038/bmt.2016.157
Published Online: 2016-06-06
Published Print: 2016-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Horn, B
O'Kane, S
Wattier, R L
Wahlstrom, J T
Melton, A
Cowan, M J
Dvorak, C C
Text and Data Mining valid from 2016-06-06
Version of Record valid from 2016-06-06
Article History
First Online: 6 June 2016
Competing interests
: The authors declare no conflict of interest.